ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SNGX Soligenix Inc

0.3937
-0.0203 (-4.90%)
Last Updated: 04:41:31
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Soligenix Inc SNGX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0203 -4.90% 0.3937 04:41:31
Open Price Low Price High Price Close Price Previous Close
0.4101 0.393 0.4154 0.414
more quote information »

Recent News

Date Time Source Heading
25/4/202421:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18/4/202422:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15/4/202421:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11/4/202421:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03/4/202422:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15/3/202422:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08/2/202423:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25/1/202423:30PRNUSSoligenix to Present at The Microcap Conference
08/1/202423:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04/1/202423:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02/1/202423:30PRNUSSoligenix Announces Publication Demonstrating Complete..
23/12/202308:05EDGAR2Form 8-K - Current report
18/12/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
16/12/202308:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:03EDGAR2Form 8-K - Current report
09/12/202309:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202309:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202309:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202309:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202308:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/12/202323:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30/11/202323:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
18/11/202308:05EDGAR2Form 8-K - Current report
18/11/202308:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
14/11/202308:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202323:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
21/10/202307:05EDGAR2Form 8-K - Current report
21/10/202307:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
18/10/202304:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/10/202304:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/10/202307:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202322:30PRNUSSoligenix to Present at The ThinkEquity Conference
14/10/202304:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/9/202321:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
23/9/202306:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/9/202306:05EDGAR2Form 8-K - Current report
23/9/202306:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
16/9/202306:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/9/202306:05EDGAR2Form 8-K - Current report
31/8/202306:05EDGAR2Form S-3 - Registration statement under Securities Act of..
22/8/202307:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/8/202321:30PRNUSSoligenix Announces Recent Accomplishments And Second..
15/8/202306:09EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/8/202321:30PRNUSHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
08/8/202306:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/8/202306:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/7/202321:30PRNUSSoligenix Announces Expansion of SGX302 (Synthetic..

Your Recent History

Delayed Upgrade Clock